{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T18:44:27Z","timestamp":1785869067579,"version":"3.56.0"},"reference-count":43,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"unspecified","delay-in-days":24,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"the Basic Research Plan of Natural Science in Shaanxi Province","award":["2023-JC-ZD-41"],"award-info":[{"award-number":["2023-JC-ZD-41"]}]},{"name":"the Basic Research Plan of Natural Science in Shaanxi Province","award":["2023-JC-ZD-45"],"award-info":[{"award-number":["2023-JC-ZD-45"]}]},{"name":"the Basic Research Plan of Natural Science in Shaanxi Province","award":["2024SF-YBXM-139"],"award-info":[{"award-number":["2024SF-YBXM-139"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872482"],"award-info":[{"award-number":["81872482"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82130084"],"award-info":[{"award-number":["82130084"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203336"],"award-info":[{"award-number":["82203336"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,7,2]]},"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of hematological malignancies; however, it faces significant challenges in treating solid tumors, including limited immune infiltration into tumor tissues and immunosuppressive tumor microenvironment. Oncolytic viruses (OVs), which selectively destroy cancer cells and trigger antitumor immune responses, offer a compelling solution to these challenges. Newcastle disease virus (NDV) is a natural OV that exhibits antitumor activity with minimal side effects in clinical studies. We hypothesized that combining NDV, engineered to express a chemokine, with tetracycline-inducible CAR T cells could synergistically enhance CAR T cell therapy efficacy against solid tumors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We constructed a recombinant NDV expressing human CCL19 (rNDV19) and evaluated its therapeutic efficacy alongside doxycycline-inducible CAR T cells in an orthotopic lung cancer mouse model. Tumor burden, immune cell infiltration, and mouse survival were analyzed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>rNDV19 retained potent oncolytic activity, significantly reducing tumor cell viability while achieving stable expression of human CCL19. rNDV19 triggered significant recruitment of CAR T cells into tumors and promoted their activity. Mechanistic analysis revealed that rNDV19 and CAR T cell combination therapy remodeled the tumor microenvironment. Transcriptomic profiling highlighted activation of critical immune pathways\u2014including leukocyte chemotaxis, T cell differentiation, cytokine production, and immune response-activating signaling in combination therapy. These findings were further corroborated by upregulated expression of T cell activation markers like IL-2, TNF-\u03b1, IFN-\u03b3, and cytotoxic effector molecules such as granzyme A and perforin. Therapeutically, the combination synergistically extended median survival time from 22 to 36 days, outperforming monotherapies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The combination of rNDV19 and CAR T cells represents a promising strategy for overcoming the limitations of CAR T cell therapy for solid tumors. This approach enhances immune cell infiltration and activation, potentially converting \u201ccold\u201d tumors into \u201chot\u201d tumors to improve therapeutic outcomes and offering a robust translational framework for solid tumor immunotherapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2025-011783","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T10:20:22Z","timestamp":1753438822000},"page":"e011783","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":11,"title":["hCCL19-expressing recombinant Newcastle disease virus boosts CAR T cell infiltration and efficacy in solid tumor"],"prefix":"10.1136","volume":"13","author":[{"given":"Man","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Cell Biology and National Translational Science Center for Molecular Medicine, Fourth Military Medical University, Xi'an, China"},{"name":"State Key Laboratory of New Targets Discovery and Drug Development for Major Diseases, Xi'an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Cell Biology and National Translational Science Center for Molecular Medicine, Fourth Military Medical University, Xi'an, China"},{"name":"State Key Laboratory of New Targets Discovery and Drug Development for Major Diseases, Xi'an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan-Ting","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Cell Biology and National Translational Science Center for Molecular Medicine, Fourth Military Medical University, Xi'an, China"},{"name":"State Key Laboratory of New Targets Discovery and Drug Development for Major Diseases, Xi'an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren-Yu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Cell Biology and National Translational Science Center for Molecular Medicine, Fourth Military Medical University, Xi'an, China"},{"name":"State Key Laboratory of New Targets Discovery and Drug Development for Major Diseases, Xi'an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Liang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Cell Biology and National Translational Science Center for Molecular Medicine, Fourth Military Medical University, Xi'an, China"},{"name":"State Key Laboratory of New Targets Discovery and Drug Development for Major Diseases, Xi'an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Health Statistics, Fourth Military Medical University, Xi'an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Jiao","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Cell Biology and National Translational Science Center for Molecular Medicine, Fourth Military Medical University, Xi'an, China"},{"name":"State Key Laboratory of New Targets Discovery and Drug Development for Major Diseases, Xi'an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Cell Biology and National Translational Science Center for Molecular Medicine, Fourth Military Medical University, Xi'an, China"},{"name":"State Key Laboratory of New Targets Discovery and Drug Development for Major Diseases, Xi'an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze-Kun","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Cell Biology and National Translational Science Center for Molecular Medicine, Fourth Military Medical University, Xi'an, China"},{"name":"State Key Laboratory of New Targets Discovery and Drug Development for Major Diseases, Xi'an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Le","family":"Yong","sequence":"additional","affiliation":[{"name":"Department of Cell Biology and National Translational Science Center for Molecular Medicine, Fourth Military Medical University, Xi'an, China"},{"name":"State Key Laboratory of New Targets Discovery and Drug Development for Major Diseases, Xi'an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang-Min","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Cell Biology and National Translational Science Center for Molecular Medicine, Fourth Military Medical University, Xi'an, China"},{"name":"State Key Laboratory of New Targets Discovery and Drug Development for Major Diseases, Xi'an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Yong","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Cell Biology and National Translational Science Center for Molecular Medicine, Fourth Military Medical University, Xi'an, China"},{"name":"State Key Laboratory of New Targets Discovery and Drug Development for Major Diseases, Xi'an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-Min","family":"Kong","sequence":"additional","affiliation":[{"name":"Department of Cell Biology and National Translational Science Center for Molecular Medicine, Fourth Military Medical University, Xi'an, China"},{"name":"State Key Laboratory of New Targets Discovery and Drug Development for Major Diseases, Xi'an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Transfusion Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Nan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Cell Biology and National Translational Science Center for Molecular Medicine, Fourth Military Medical University, Xi'an, China"},{"name":"State Key Laboratory of New Targets Discovery and Drug Development for Major Diseases, Xi'an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijie","family":"Bian","sequence":"additional","affiliation":[{"name":"Department of Cell Biology and National Translational Science Center for Molecular Medicine, Fourth Military Medical University, Xi'an, China"},{"name":"State Key Laboratory of New Targets Discovery and Drug Development for Major Diseases, Xi'an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4129-0983","authenticated-orcid":false,"given":"Ding","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Cell Biology and National Translational Science Center for Molecular Medicine, Fourth Military Medical University, Xi'an, China"},{"name":"State Key Laboratory of New Targets Discovery and Drug Development for Major Diseases, Xi'an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,7,25]]},"reference":[{"key":"2025100305295171000_13.7.e011783.1","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","article-title":"CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors","volume":"21","author":"Peng","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"2025100305295171000_13.7.e011783.2","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002723","article-title":"Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead","volume":"9","author":"Kirtane","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025100305295171000_13.7.e011783.3","unstructured":"FDA approves new car t-cell therapy for all. Available: https:\/\/www.aabb.org\/news-resources\/news\/article\/2024\/11\/12\/fda-approves-new-car-t-cell-therapy-for-all [Accessed 15 Nov 2024]."},{"key":"2025100305295171000_13.7.e011783.4","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1053\/j.seminhematol.2024.07.003","article-title":"Tuning CAR T-cell therapies for efficacy and reduced toxicity","volume":"61","author":"Blud","year":"2024","journal-title":"Semin Hematol"},{"key":"2025100305295171000_13.7.e011783.5","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/s41587-024-02446-2","article-title":"Beyond the blood: expanding CAR T cell therapy to solid tumors","volume":"43","author":"Uslu","year":"2025","journal-title":"Nat Biotechnol"},{"key":"2025100305295171000_13.7.e011783.6","doi-asserted-by":"crossref","first-page":"100543","DOI":"10.1016\/j.xcrm.2022.100543","article-title":"Harnessing the chemokine system to home CAR-T cells into solid tumors","volume":"3","author":"Foeng","year":"2022","journal-title":"Cell Reports Medicine"},{"key":"2025100305295171000_13.7.e011783.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2023.09.021"},{"key":"2025100305295171000_13.7.e011783.8","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-024-01625-7","article-title":"Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies","volume":"17","author":"Ai","year":"2024","journal-title":"J Hematol Oncol"},{"key":"2025100305295171000_13.7.e011783.9","doi-asserted-by":"publisher","DOI":"10.7150\/thno.76854"},{"key":"2025100305295171000_13.7.e011783.10","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1455163","article-title":"Oncolytic virus and CAR-T cell therapy in solid tumors","volume":"15","author":"Ponterio","year":"2024","journal-title":"Front Immunol"},{"key":"2025100305295171000_13.7.e011783.11","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4663"},{"key":"2025100305295171000_13.7.e011783.12","doi-asserted-by":"crossref","first-page":"108103","DOI":"10.1016\/j.pharmthera.2021.108103","article-title":"Oncolytic ImmunoViroTherapy: A long history of crosstalk between viruses and immune system for cancer treatment","volume":"236","author":"Feola","year":"2022","journal-title":"Pharmacol Ther"},{"key":"2025100305295171000_13.7.e011783.13","doi-asserted-by":"crossref","first-page":"176913","DOI":"10.1016\/j.ejphar.2024.176913","article-title":"Immunogenic cell death-based oncolytic virus therapy: A sharp sword of tumor immunotherapy","volume":"981","author":"Zhang","year":"2024","journal-title":"Eur J Pharmacol"},{"key":"2025100305295171000_13.7.e011783.14","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ymthe.2022.08.021","article-title":"CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma","volume":"31","author":"Wang","year":"2023","journal-title":"Mol Ther"},{"key":"2025100305295171000_13.7.e011783.15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49989-1"},{"key":"2025100305295171000_13.7.e011783.16","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2015.1037058"},{"key":"2025100305295171000_13.7.e011783.17","unstructured":"David MK , Peter MH . Fields of viology. 6th edn. Philadelphia, PA, USA: Lippincott Williams & Wilkins, 2013."},{"key":"2025100305295171000_13.7.e011783.18","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12123552","article-title":"Newcastle Disease Virus at the Forefront of Cancer Immunotherapy","volume":"12","author":"Burman","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2025100305295171000_13.7.e011783.19","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2011.207"},{"key":"2025100305295171000_13.7.e011783.20","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-015-0271-1","article-title":"Oncolytic Newcastle disease virus expressing chimeric antibody enhanced anti-tumor efficacy in orthotopic hepatoma-bearing mice","volume":"34","author":"Wei","year":"2015","journal-title":"J Exp Clin Cancer Res"},{"key":"2025100305295171000_13.7.e011783.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2008.03.003"},{"key":"2025100305295171000_13.7.e011783.22","doi-asserted-by":"crossref","DOI":"10.1186\/s40364-022-00434-9","article-title":"Strategies to enhance CAR-T persistence","volume":"10","author":"Liu","year":"2022","journal-title":"Biomark Res"},{"key":"2025100305295171000_13.7.e011783.23","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2019.00212","article-title":"CCL19 and CCR7 Expression, Signaling Pathways, and Adjuvant Functions in Viral Infection and Prevention","volume":"7","author":"Yan","year":"2019","journal-title":"Front Cell Dev Biol"},{"key":"2025100305295171000_13.7.e011783.24","doi-asserted-by":"crossref","first-page":"907","DOI":"10.4049\/jimmunol.2300049","article-title":"Memory T Cells in the Immunoprevention of Cancer: A Switch from Therapeutic to Prophylactic Approaches","volume":"211","author":"Mittra","year":"2023","journal-title":"J Immunol"},{"key":"2025100305295171000_13.7.e011783.25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-683847"},{"key":"2025100305295171000_13.7.e011783.26","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-021-01128-9","article-title":"IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin","volume":"14","author":"Pang","year":"2021","journal-title":"J Hematol Oncol"},{"key":"2025100305295171000_13.7.e011783.27","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.4086"},{"key":"2025100305295171000_13.7.e011783.28","doi-asserted-by":"crossref","first-page":"12369","DOI":"10.18632\/aging.205184","article-title":"CCL19: a novel prognostic chemokine modulates the tumor immune microenvironment and outcomes of cancers","volume":"15","author":"Gu","year":"2023","journal-title":"Aging (Albany NY)"},{"key":"2025100305295171000_13.7.e011783.29","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2019.00233","article-title":"Doxycycline Inducible Chimeric Antigen Receptor T Cells Targeting CD147 for Hepatocellular Carcinoma Therapy","volume":"7","author":"Zhang","year":"2019","journal-title":"Front Cell Dev Biol"},{"key":"2025100305295171000_13.7.e011783.30","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/15384047.2016.1276126","article-title":"Metuzumab enhanced chemosensitivity and apoptosis in non-small cell lung carcinoma","volume":"18","author":"Feng","year":"2017","journal-title":"Cancer Biol Ther"},{"key":"2025100305295171000_13.7.e011783.31","doi-asserted-by":"crossref","DOI":"10.1186\/s13059-017-1349-1","article-title":"xCell: digitally portraying the tissue cellular heterogeneity landscape","volume":"18","author":"Aran","year":"2017","journal-title":"Genome Biol"},{"key":"2025100305295171000_13.7.e011783.32","doi-asserted-by":"crossref","DOI":"10.1016\/j.omton.2024.200809","article-title":"Emerging delivery strategy for oncolytic virotherapy","volume":"32","author":"Zhu","year":"2024","journal-title":"Mol Ther Oncol"},{"key":"2025100305295171000_13.7.e011783.33","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-023-01723-z","article-title":"CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances","volume":"22","author":"Maalej","year":"2023","journal-title":"Mol Cancer"},{"key":"2025100305295171000_13.7.e011783.34","doi-asserted-by":"crossref","first-page":"790150","DOI":"10.3389\/fcell.2021.790150","article-title":"Oncolytic Virotherapy: From Bench to Bedside","volume":"9","author":"Yang","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"2025100305295171000_13.7.e011783.35","doi-asserted-by":"crossref","first-page":"5833","DOI":"10.1016\/j.sjbs.2021.06.043","article-title":"Antitumor immunity enhancement through Newcastle viral oncolysate in mice model: A promising method to treat tumors","volume":"28","author":"Mozaffari Nejad","year":"2021","journal-title":"Saudi J Biol Sci"},{"key":"2025100305295171000_13.7.e011783.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2024.12.010"},{"key":"2025100305295171000_13.7.e011783.37","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009336","article-title":"Phase I study of a recombinant attenuated oncolytic virus, MEDI5395 (NDV-GM-CSF), administered systemically in combination with durvalumab in patients with advanced solid tumors","volume":"12","author":"Davar","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2025100305295171000_13.7.e011783.38","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.1A0314-170R"},{"key":"2025100305295171000_13.7.e011783.39","doi-asserted-by":"publisher","DOI":"10.1111\/imcb.12254"},{"key":"2025100305295171000_13.7.e011783.40","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1158\/2767-9764.CRC-24-0226","article-title":"Therapeutic Efficacy of IL7\/CCL19-Expressing CAR-T Cells in Intractable Solid Tumor Models of Glioblastoma and Pancreatic Cancer","volume":"4","author":"Ohta","year":"2024","journal-title":"Cancer Res Commun"},{"key":"2025100305295171000_13.7.e011783.41","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1007\/s10565-023-09821-w","article-title":"GPC3-IL7-CCL19-CAR-T primes immune microenvironment reconstitution for hepatocellular carcinoma therapy","volume":"39","author":"Lu","year":"2023","journal-title":"Cell Biol Toxicol"},{"key":"2025100305295171000_13.7.e011783.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.07.006"},{"key":"2025100305295171000_13.7.e011783.43","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.omtm.2020.01.001","article-title":"Oncolytic Viruses and the Immune System: The Dynamic Duo","volume":"17","author":"Lemos de Matos","year":"2020","journal-title":"Mol Ther Methods Clin Dev"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-011783","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T12:30:02Z","timestamp":1759494602000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-011783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":43,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7,25]]},"published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1136\/jitc-2025-011783"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-011783","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}